



11/ Prior  
Art Unit

PATENT  
ATTORNEY DOCKET NO.: 056291-5044

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

BROWN

Appln. No.: 09/936,758

Filed: November 15, 2001

FOR: AMIDE DERIVATIVES

)  
)  
)  
) Group Art Unit: 1626  
)  
) Examiner: SAEED, Kamal A.  
)  
)

Commissioner of Patents  
Washington, D.C. 20231

Date: January 6, 2003

Sir:

**INFORMATION DISCLOSURE STATEMENT**

**Citation of Related U.S. Patent Applications**

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Inventor	U.S. Serial No.	U.S. Filing Date	PCT Publication No.	PCT Publication Date
Brown et al.	09/508,055 <b>US 6,498,274</b>	07-Mar-2000	PCT/GB98/02826 WO 99/15164	01-Apr-1999
Brown et al.	10/192,495	10-Sep-2002	PCT/GB98/02826 <b>WO 99/15164</b>	01-Apr-1999
Hedge et al.	09/308,173		PCT/GB97/03012 <b>WO 98/22103</b>	28-May-1998
Brown et al.	09/674,560	02-Nov-2000	PCT/GB99/01489 <b>WO 99/59959</b>	25-Nov-1999
Brown	09/674,428 <b>US 6,465,455</b>	01-Nov-2000	PCT/GB99/01491 WO 99/59960	25-Nov-1999
Brown et al.	09/762,106	02-Feb-2001	PCT/GB99/02494 <b>WO 00/07980</b>	17-Feb-2000
Brown et al.	09/762,107 <b>US 6,432,949</b>	02-Feb-2001	PCT/GB99/02489 WO 00/07991	17-Feb-2000

Inventor	U.S. Serial No.	U.S. Filing Date	PCT Publication No.	PCT Publication Date
Brown et al.	09/787,882 <b>US 6,455,520</b>	23-Mar-2001	PCT/GB99/03144 WO 00/18738	06-Apr-2000
Cumming	09/787,883	23-Mar-2001	PCT/GB99/03220 <b>WO 00/20402</b>	13-Apr-2000
Brown et al.	09/936,698	17-Sep-2001	PCT/GB00/00914 <b>WO 00/55120</b>	21-Sep-2000
Cumming	09/937,018	20-Sep-2001	PCT/GB00/01006 <b>WO 00/56738</b>	28-Sep-2000
Cumming	10/070,360	05-Mar-2002	PCT/GB00/03929 <b>WO 01/27089</b>	19-Apr-2001

The undersigned understands that the text of each related application is essentially the same as the corresponding published PCT Application. The issued US Patent or the corresponding PCT published application for each related application is cited in the accompanying Form PTO-1449 and a copy is provided with this Information Disclosure Statement.

**PLEASE DO NOT PRINT** the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

### Citation of Documents

Attached is a Form PTO-1449 listing the enclosed documents.


The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

### Comments on Related Applications

Applicant makes the following observations with respect to certain of the structural distinctions between the above-listed related applications:

Application No. 09/508,055 (now US Patent 6,498,274, having a divisional pending as Application No. 10/192,495) concerns a compound of the formula I:



Formula I

All of the above-mentioned applications are concerned with such "bis-amide" compounds which have the essential structural feature of a central phenyl ring which bears an  $R^3$  group

and two amide groups (usually both -NHCO- groups as in the above Formula I but sometimes one -NHCO- group and one -CONH- group) which are located in a 1,3-relationship on the central phenyl ring.

In Application No. 09/308,173 and Application No. 09/508,055, as in Formula I above, the amide group to the left of the central phenyl ring is linked to a second phenyl ring substituted by a  $(R^1)_m$  group whereas the amide group to the right of the central phenyl ring is linked via a  $(CH_2)_q$  group to an optionally substituted third ring (aryl or cycloalkyl). Application No. 09/308,173 is concerned with the compounds and their anti-tumor activity. Application No. 09/508,055 is concerned with their use as cytokine inhibitors.

In Application No. 09/674,428 (now US Patent 6,465,455), the  $R^3$  group is, for example, halogeno whereas in Application No. 09/508,055, the  $R^3$  group is (1-4C)alkyl.

In Application No. 09/674,560, a more extensive range of  $(R^1)_m$  substituents is specified.

In Application No. 09/762,106, the amide group to the right of the central phenyl ring is reversed (-CONH- rather than -NHCO-).

In Application No. 09/762,107 (now US Patent 6,432,949), the amide group to the left of the central phenyl ring is linked directly to a heteroaryl ring rather than to a second phenyl ring.

In Application No. 09/787,882 (now US Patent 6,455,500), the amide group to the right of the central phenyl ring is linked to an optionally substituted heteroaryl ring rather than to a third phenyl ring.

In Application No. 09/787,883, the central phenyl ring bears one amide group (-NHCO-) to the right of the central phenyl ring but the CO portion of the other amide group is replaced by the heteroatom-containing portion of a quinoline or quinazoline ring.

In Application No. 09/936,698, the amide group to the left of the central phenyl ring is reversed (-NHCO- rather than -CONH-).


In Application No. 09/936,758 (the present application), one of the amide groups is constrained within a 3,4-dihydroquinazoline-4-one ring.

In Application No. 09/937,018, the central phenyl ring bears one amide group (-NHCO-) to the right of the central phenyl ring but the CO portion of the other amide group is replaced by the heteroatom-containing portion of a bicyclic heteroaryl ring (other than the quinoline or quinazoline ring of Application No. 09/787,883).

In Application No. 10/070,360, the central phenyl ring bears one amide group (-NHCO-) to the right of the central phenyl ring but the CO portion of the other amide group is replaced by a pyrimidine ring.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



Date: January 3, 2003  
Morgan Lewis & Bockius LLP  
Customer No. **009629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000  
DJB:mk

By:

---

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001